Study Shows Chemotherapy Combination Effective for Mesothelioma Patients

The remote server returned an unexpected response: (417) Expectation failed.
The remote server returned an unexpected response: (417) Expectation failed.

March 15, 2012 /24-7PressRelease/ -- Individuals suffering from Mesothelioma know all too well the aggressive nature of the disease. Fortunately, a new clinical trial shows positive results for some patients taking a particular type of chemotherapy combination.

What is Mesothelioma?

Mesothelioma is a rare type of cancer that afflicts the meothelium or thin membrane that covers a person's lungs, heart and other vital organs. The cancer is most commonly caused by the inhalation of microscopic asbestos fibers.

Asbestos fibers were first used by U.S. manufacturers and builders in the late 19th century as an insulator for electrical components and insulation in buildings because of their sound absorption qualities, strength, and resistance to fire and heat. In the midst of World War II, other industries, including steel mills, power and paper plants, shipbuilders and mariners began using asbestos. However, at the turn of the century, the public began to learn just how dangerous the product really was.

In the early 1900s, a significant percentage of people located in various mining towns across the country known to use asbestos were succumbing to lung problems and even died. Authorities tied the illnesses to asbestos and in the late 1970s, the U.S. Consumer Product Safety Commission--the federal agency in charge of protecting the public from injury or death resulting from consumer products--banned the manufacture and use of asbestos in certain consumer products. In 1989, all new uses of asbestos in all products were officially halted in the U.S.

Mesothelioma Treatment

Mesothelioma is one of the most serious and aggressive forms of cancer and has proved resistant to most kinds of treatment; possibly because symptoms of the disease do not appear until years after a person's exposure to asbestos which provides plenty of time for the cancer to grow and metastasize to other parts of the human body.

Today, chemotherapy is the traditional form used to fight the disease, but even this type of treatment is shown to result in only moderate impacts for patients. However, a group of research scientists in the Netherlands may have found the right chemo combination.

The Study

Between 1995 and 2006, three Dutch scientists analyzed roughly 4700 mesothelioma patients diagnosed with the condition and found that median survival rates for patients receiving the cisplatin-antifolate chemotherapy combination jumped from approximately 10 months to over 13 months.

Cisplatin, marketed as Platinol, is known to trigger apoptosis or death of the cancer cells. Cisplatin is then combined with antifolate (Alimta), a drug that blocks the activity of folic acid inside cells that interrupt cellular metabolism.

The study's authors, however, noted that outside factors could also play a part in the increase in survival time. "Due to the observational nature of this study alternative explanations cannot be excluded," one author noted. Further, the survival rates for peritoneal mesothelioma patients still remained poor.

Asbestos Exposure Today

Today, despite the prohibition on the manufacture and use of new products containing asbestos within the United States, many people are still at risk of being exposed to the dangerous product.

Since asbestos was utilized up until the late 1970s, many building or electrical materials in homes and commercial properties built before then still contain asbestos. Many workers or construction technicians remodeling, repairing, demolishing or renovating these properties today often disturb the asbestos within the materials. When disturbed, the fibers become airborne and ultimately inhaled by those within the vicinity of the construction project.

Luckily, countries, including the U.S., have promulgated rules to help minimize individuals' exposure to asbestos today. The Occupational Safety and Health Administration--the federal agency known as OSHA responsible for enforcing health and safety regulations--has implemented protocols that must be followed by anyone dealing with the repair, renovation, demolition, or maintenance of any structure that contains asbestos. In addition, the agency has employed asbestos spill and clean-up procedures as well as rules regarding the transportation, storage, and disposal of products containing asbestos.

The Fight Continues

It remains to be seen just how extensive and how long the damage associated with asbestos will have on individuals who have been or who potentially will be exposed to this hazardous product. It's estimated that over 2,000 individuals are diagnosed with mesothelioma every year. However, one thing is certain--the fight to mitigate the effects of this horrible disease, as demonstrated by continuous efforts from both the U.S. and countries abroad, will continue.

An Attorney Can Help

If you or a loved one has developed the symptoms of mesothelioma or asbestosis, contact an attorney experienced in asbestos litigation immediately. An experienced attorney can advise you of your rights and hold the responsible parties accountable.

Article provided by Law Offices of Wallace & Graham
Visit us at http://www.usmesotheliomalaw.com/

---
Press release service and press release distribution provided by http://www.24-7pressrelease.com

# # #

Read more Press Releases from FL Web Advantage:

View the original article here

Peliculas Online

Lung Cancer Screening Might Pay Off, Analysis Shows

IP is over the quota
IP is over the quota

MONDAY, April 9 (HealthDay News) -- Screening people at high risk for lung cancer could be at least as cost-effective as screening for breast, colorectal and cervical cancers, a new study suggests.

A group of actuaries specializing in the health care industry estimated how much private insurance companies would pay and the survival benefits that would follow if they covered lung cancer screening. They based their study on using a scanning technology called low-dose spiral computed tomography (CT) on people between the ages of 50 and 64 who were at high risk for developing lung cancer due to their smoking history.

The authors estimated that screening high-risk people would cost providers less than $19,000 for every year of life saved. The study was published in the April issue of Health Affairs.

In comparison, the costs per life-year saved for breast, colorectal and cervical cancer screening -- the three types of screening that have widespread support in the United States -- are at least about $31,000, $19,000 and $50,000, respectively, according to the authors, who updated estimates from previous analyses.

The authors also estimated that insurance rates would increase by 76 cents per month if half of the eligible members got screening.

"[Lung cancer] is a very deadly kind of cancer, but it is also concentrated in a relatively small group of people who have a history of smoking. That's why the economics makes such powerful sense here," said study author Bruce Pyenson, a principal and consulting actuary at Milliman, based in New York City.

About 220,000 people will be diagnosed with lung cancer and 160,000 will die from the disease in 2012, according to the American Cancer Society. The five-year survival rate after diagnosis is only about 16 percent, in part because most people have advanced lung cancer by the time they are diagnosed.

Most health organizations do not recommend lung cancer screening, or testing people before they have symptoms. The U.S. Preventive Services Task Force (USPSTF) does not support CT scan, chest X-rays or sputum cytology, in which mucus from the lungs is examined, because it states that there is not enough evidence that these tests reduce the number of lung cancer deaths.

On the other hand, lung cancer screening can detect benign tumors, leading to unnecessary invasive biopsies, and increases radiation exposure.

The USPSTF guidelines are probably the "single most important factor" for Medicare and private insurance companies in deciding whether or not to cover lung cancer screening, said Dr. William Black, a radiologist at Dartmouth-Hitchcock Medical Center in Lebanon, N.H.

And while neither the USPSTF nor insurance companies base their guidelines or coverage on costs, the USPSTF often looks at proxies to cost like the number of people needed to treat to have a certain effect, Black explained.

"Although in the past [cost] has not been a criteria for Medicare, many people expect that to change," Pyenson said. "Expenditure in health care overall is not sustainable."

In addition to the current study suggesting the cost-effectiveness of lung cancer screening, recent support for screening came in 2011 when results of the National Lung Screening Trial (NLST) were published. It found that getting CT scans every year for three years reduced lung cancer deaths by 20 percent compared with chest X-rays in current or former smokers between 55 and 74 years of age.

"I think it's certainly possible the USPSTF will endorse it, but if they did they would definitely restrict it to people like in the NLST," Black said, adding that he expects that the Task Force will update its guidelines sometime in 2013.

The current study simulated the effect of annual CT scans in people between 50 and 64 who had smoked at least a pack of cigarettes a day for 30 years. The group did not include people older than 64 because that is when Medicare kicks in and it would be more difficult to determine the cost to private insurers, Pyenson explained. The research was funded by the Lung Cancer Alliance and the American Legacy Foundation.

Pyenson and his colleagues estimated the number of deaths associated with early and late stages of lung cancer over a 15-year period (to reflect the 15 years between ages 50 and 64).

To estimate the number of life-years saved by lung cancer screening, the group used data collected from lung cancer screening programs to predict at what stage lung cancers would have been detected if screening had been in place and as a result how many fewer lung cancer deaths there would have been.

Although the authors concluded that cost-benefit ratio for lung cancer screening is relatively low, one expert suggested they might be underestimating the total cost.

"I can't imagine how it could be that low," said Pamela McMahon, associate director of the Massachusetts General Hospital Institute for Technology Assessment in Boston.

In a 2011 study, McMahon and her colleagues estimated that annual CT screening for people between 50 and 74 who had smoked at least one pack a day for 20 years would cost between $126,000 and $169,000 for every quality-adjusted life-year.

One important difference with McMahon's analysis is that her group considered all costs associated with screening, such as how much a patient would spend to travel to the clinic once a year for screening. "I would imagine this cost is going to be pretty different," McMahon said.

Nonetheless, McMahon thinks that lung cancer screening will eventually be adopted in the United States. "Whether it will be as inexpensive as $19,000 or as expensive as we estimated remains to be seen," she noted.

In addition, McMahon's study found that the cost effectiveness got a boost when screening had an effect on smoking quit rates. If getting screened doubled quit rates, the cost effectiveness for a 50-year-old who smoked a pack a day for 20 years was $75,000 per quality-adjusted life-year.

"I think that smoking cessation programs should definitely be part of whatever screening programs get adopted," McMahon said.

More information

To learn more about lung cancer and screening, visit the American Cancer Society.

SOURCES: Bruce Pyenson, principal and consulting actuary, Milliman, New York City; William Black, M.D., professor, radiology, Dartmouth-Hitchcock Medical Center, Lebanon, N.H.; Pamela McMahon, Ph.D., associate director, Massachusetts General Hospital Institute for Technology Assessment, and assistant professor, radiology, Harvard Medical School, Boston; April 2012, Health Affairs

Copyright © 2012 HealthDay. All rights reserved.

View the original article here

Peliculas Online